Virologic and biochemical responses to clevudine in patients with chronic HBV infection- associated cirrhosis: Data at week 48

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages 287-293

  Kim, J H ^a,a   Yim, Hyung Joon ^a   Jung, E S ^a   Jung, Y K ^a   Seo, Y S ^a   Yeon, J E ^a   Lee, H S ^a   Um, S H ^a   Byun, K S ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Biochemical response; Clevudine; Liver cirrhosis; Virologic response

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; TREATMENT RESPONSE; VIRUS IMMUNITY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; KOREA; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79952661112     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01304.x     Document Type: Article

References (35)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745. (Pubitemid 27527771)
2. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861. (Pubitemid 38337668)
3. Lee KS, Byun KS, Chung YH et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy. Intervirology 2007; 50: 296-302. (Pubitemid 47091847)
4. Yoo BC, Kim JH, Chung YH et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-1178.
5. Yoo BC, Kim JH, Kim TH et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 1041-1048.
6. Marcellin P, Mommeja-Marin H, Sacks SL et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-148. (Pubitemid 38868933)
7. Lee HS, Chung YH, Lee K et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 982-988. (Pubitemid 43724623)
8. Kim BK, Oh J, Kwon SY et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009; 51: 829-834.
9. Seok JI, Lee DK, Lee CH et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009; 49: 2080-2086.
10. Lee CH, Kim SO, Byun KS et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-1152.
11. Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-1495. (Pubitemid 44476796)
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
14. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
15. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313. (Pubitemid 32176454)
16. Hui CK, Lau GK. Current issues and future directions in treatment. Semin Liver Dis 2006; 26: 192-197. (Pubitemid 43668261)
17. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
18. Schiff E, Simsek H, Lee WM et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-2783.
19. Kanwal F, Farid M, Martin P et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 2076-2089. (Pubitemid 44337634)
20. Chu CK, Ma T, Shanmuganathan K et al. Use of 2′-fluoro-5-methyl- beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979-981.
21. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5- methyl-beta-L-arabinofuranosyluracil. Biochem Pharmacol 1996; 51: 941-947.
22. Chin R, Shaw T, Torresi J et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 2495-2501.
23. Korba BE, Furman PA, Otto MJ. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev Anti Infect Ther 2006; 4: 549-561. (Pubitemid 44523935)
24. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975. (Pubitemid 28419565)
25. Schirren CA, Jung MC, Zachoval R et al. Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions. Clin Exp Immunol 1997; 108: 144-150. (Pubitemid 27140342)
26. Sobao Y, Tomiyama H, Sugi K et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002; 36: 105-115. (Pubitemid 34234024)
27. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-4927. (Pubitemid 36402840)
28. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439-1449. (Pubitemid 43827198)
29. Tak WY, Park SY, Jung MK et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res 2009; 39: 944-947.
30. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624. (Pubitemid 32927983)
31. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-1415. (Pubitemid 35407438)
32. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98: 2261-2267. (Pubitemid 37305368)
33. Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004; 19: 25-37. (Pubitemid 38125635)
34. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270. (Pubitemid 34146434)
35. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39(Suppl. 1): S50-S58. (Pubitemid 37222647)